Autologous hematopoietic stem cell transplantation in remission consolidation of acute myeloid leukemia with initially unfavorable prognostic factors

Introduction. The role of autologous hematopoietic stem cell transplantation (autoHSCT) in adult patients with acute myeloid leukemia (AML) with poor prognosis factors is not completely defined.Purpose: to present the results of a multicenter prospective study of autoHSCT efficacy in AML patients wi...

Full description

Saved in:
Bibliographic Details
Main Authors: G. D. Petrova, K. N. Melkova, N. V. Gorbunova, T. Z. Chernyavskaya, V. A. Doronin, V. N. Kostrykina, O. P. Trofimova, I. Yu. Grivtsova, N. N. Tupitsyn
Format: Article
Language:Russian
Published: ABV-press 2016-03-01
Series:Онкогематология
Subjects:
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/183
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849689965483524096
author G. D. Petrova
K. N. Melkova
N. V. Gorbunova
T. Z. Chernyavskaya
V. A. Doronin
V. N. Kostrykina
O. P. Trofimova
I. Yu. Grivtsova
N. N. Tupitsyn
author_facet G. D. Petrova
K. N. Melkova
N. V. Gorbunova
T. Z. Chernyavskaya
V. A. Doronin
V. N. Kostrykina
O. P. Trofimova
I. Yu. Grivtsova
N. N. Tupitsyn
author_sort G. D. Petrova
collection DOAJ
description Introduction. The role of autologous hematopoietic stem cell transplantation (autoHSCT) in adult patients with acute myeloid leukemia (AML) with poor prognosis factors is not completely defined.Purpose: to present the results of a multicenter prospective study of autoHSCT efficacy in AML patients with initially unfavorable prognostic factors.Materials and methods. From 2007 to 2014, 42 patients with primary AML with one or more poor prognosis factors were included in the study. AutoHSCT was performed in 16 patients (9 women) aged 20–57 years (median 38 years) without available compatible allogeneic (related or unrelated) donor. In order to identify the role of different prognostic factors the long-term results were analyzed.Results. With a median follow up of 49 months (range 5–86 months) 5-years overall survival, event-free survival and relapse-free survival were 47, 47 and 51 %, respectively. Rate of mortality associated with transplantation in 100 days and 2 years after autoHSCT reached 0 and 6 %, respectively. AML relapse was observed in 44 % of patients. Favorable prognostic influence of total body irradiation in conditioning regimens on the overall survival has been identified (р = 0.045).Conclusion. AutoHSCT in AML patients with initially poor prognosis factors has a long-term anti-tumor effect. In the absence of a fully compatible allogeneic donor, autoHSCT may be considered as an alternative treatment.
format Article
id doaj-art-eb302c23ecf04c56bba49019cda7de17
institution DOAJ
issn 1818-8346
2413-4023
language Russian
publishDate 2016-03-01
publisher ABV-press
record_format Article
series Онкогематология
spelling doaj-art-eb302c23ecf04c56bba49019cda7de172025-08-20T03:21:27ZrusABV-pressОнкогематология1818-83462413-40232016-03-01111526110.17650/1818-8346-2016-11-1-52-61191Autologous hematopoietic stem cell transplantation in remission consolidation of acute myeloid leukemia with initially unfavorable prognostic factorsG. D. Petrova0K. N. Melkova1N. V. Gorbunova2T. Z. Chernyavskaya3V. A. Doronin4V. N. Kostrykina5O. P. Trofimova6I. Yu. Grivtsova7N. N. Tupitsyn8N. N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, RussiaN. N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, RussiaN. N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, RussiaN. N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, RussiaN. N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, RussiaN. N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, RussiaN. N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, RussiaN. N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, RussiaN. N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, RussiaIntroduction. The role of autologous hematopoietic stem cell transplantation (autoHSCT) in adult patients with acute myeloid leukemia (AML) with poor prognosis factors is not completely defined.Purpose: to present the results of a multicenter prospective study of autoHSCT efficacy in AML patients with initially unfavorable prognostic factors.Materials and methods. From 2007 to 2014, 42 patients with primary AML with one or more poor prognosis factors were included in the study. AutoHSCT was performed in 16 patients (9 women) aged 20–57 years (median 38 years) without available compatible allogeneic (related or unrelated) donor. In order to identify the role of different prognostic factors the long-term results were analyzed.Results. With a median follow up of 49 months (range 5–86 months) 5-years overall survival, event-free survival and relapse-free survival were 47, 47 and 51 %, respectively. Rate of mortality associated with transplantation in 100 days and 2 years after autoHSCT reached 0 and 6 %, respectively. AML relapse was observed in 44 % of patients. Favorable prognostic influence of total body irradiation in conditioning regimens on the overall survival has been identified (р = 0.045).Conclusion. AutoHSCT in AML patients with initially poor prognosis factors has a long-term anti-tumor effect. In the absence of a fully compatible allogeneic donor, autoHSCT may be considered as an alternative treatment.https://oncohematology.abvpress.ru/ongm/article/view/183acute myeloid leukemiaautologous hematopoietic stem cells transplantationtotal body irradiationunfavorable prognostic factors
spellingShingle G. D. Petrova
K. N. Melkova
N. V. Gorbunova
T. Z. Chernyavskaya
V. A. Doronin
V. N. Kostrykina
O. P. Trofimova
I. Yu. Grivtsova
N. N. Tupitsyn
Autologous hematopoietic stem cell transplantation in remission consolidation of acute myeloid leukemia with initially unfavorable prognostic factors
Онкогематология
acute myeloid leukemia
autologous hematopoietic stem cells transplantation
total body irradiation
unfavorable prognostic factors
title Autologous hematopoietic stem cell transplantation in remission consolidation of acute myeloid leukemia with initially unfavorable prognostic factors
title_full Autologous hematopoietic stem cell transplantation in remission consolidation of acute myeloid leukemia with initially unfavorable prognostic factors
title_fullStr Autologous hematopoietic stem cell transplantation in remission consolidation of acute myeloid leukemia with initially unfavorable prognostic factors
title_full_unstemmed Autologous hematopoietic stem cell transplantation in remission consolidation of acute myeloid leukemia with initially unfavorable prognostic factors
title_short Autologous hematopoietic stem cell transplantation in remission consolidation of acute myeloid leukemia with initially unfavorable prognostic factors
title_sort autologous hematopoietic stem cell transplantation in remission consolidation of acute myeloid leukemia with initially unfavorable prognostic factors
topic acute myeloid leukemia
autologous hematopoietic stem cells transplantation
total body irradiation
unfavorable prognostic factors
url https://oncohematology.abvpress.ru/ongm/article/view/183
work_keys_str_mv AT gdpetrova autologoushematopoieticstemcelltransplantationinremissionconsolidationofacutemyeloidleukemiawithinitiallyunfavorableprognosticfactors
AT knmelkova autologoushematopoieticstemcelltransplantationinremissionconsolidationofacutemyeloidleukemiawithinitiallyunfavorableprognosticfactors
AT nvgorbunova autologoushematopoieticstemcelltransplantationinremissionconsolidationofacutemyeloidleukemiawithinitiallyunfavorableprognosticfactors
AT tzchernyavskaya autologoushematopoieticstemcelltransplantationinremissionconsolidationofacutemyeloidleukemiawithinitiallyunfavorableprognosticfactors
AT vadoronin autologoushematopoieticstemcelltransplantationinremissionconsolidationofacutemyeloidleukemiawithinitiallyunfavorableprognosticfactors
AT vnkostrykina autologoushematopoieticstemcelltransplantationinremissionconsolidationofacutemyeloidleukemiawithinitiallyunfavorableprognosticfactors
AT optrofimova autologoushematopoieticstemcelltransplantationinremissionconsolidationofacutemyeloidleukemiawithinitiallyunfavorableprognosticfactors
AT iyugrivtsova autologoushematopoieticstemcelltransplantationinremissionconsolidationofacutemyeloidleukemiawithinitiallyunfavorableprognosticfactors
AT nntupitsyn autologoushematopoieticstemcelltransplantationinremissionconsolidationofacutemyeloidleukemiawithinitiallyunfavorableprognosticfactors